These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 1358974)

  • 1. Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene.
    Cavallo F; Giovarelli M; Gulino A; Vacca A; Stoppacciaro A; Modesti A; Forni G
    J Immunol; 1992 Dec; 149(11):3627-35. PubMed ID: 1358974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice.
    Provinciali M; Argentati K; Tibaldi A
    Gene Ther; 2000 Apr; 7(7):624-32. PubMed ID: 10819579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory.
    Giovarelli M; Musiani P; Modesti A; Dellabona P; Casorati G; Allione A; Consalvo M; Cavallo F; di Pierro F; De Giovanni C
    J Immunol; 1995 Sep; 155(6):3112-23. PubMed ID: 7673726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different tumours, transduced with different cytokine genes as G-CSF and IL-2, show inhibition of tumour take through neutrophil activation but differ in T cell functions.
    Stoppacciaro A; Forni G; Colombo MP
    Folia Biol (Praha); 1994; 40(1-2):89-99. PubMed ID: 7525363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An efficient Th2-type memory follows CD8+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4.
    Pericle F; Giovarelli M; Colombo MP; Ferrari G; Musiani P; Modesti A; Cavallo F; Di Pierro F; Novelli F; Forni G
    J Immunol; 1994 Dec; 153(12):5659-73. PubMed ID: 7989764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha.
    Musiani P; Allione A; Modica A; Lollini PL; Giovarelli M; Cavallo F; Belardelli F; Forni G; Modesti A
    Lab Invest; 1996 Jan; 74(1):146-57. PubMed ID: 8569177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
    Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF.
    Aruga E; Aruga A; Arca MJ; Lee WM; Yang NS; Smith JW; Chang AE
    Cancer Gene Ther; 1997; 4(3):157-66. PubMed ID: 9171934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism.
    Rakhmilevich AL; Janssen K; Hao Z; Sondel PM; Yang NS
    Cancer Gene Ther; 2000 Jun; 7(6):826-38. PubMed ID: 10880012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response.
    Cavallo F; Martin-Fontecha A; Bellone M; Heltai S; Gatti E; Tornaghi P; Freschi M; Forni G; Dellabona P; Casorati G
    Eur J Immunol; 1995 May; 25(5):1154-62. PubMed ID: 7539748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The induction of in vivo proliferation of long-lived CD44hi CD8+ T cells after the injection of tumor cells expressing IFN-alpha1 into syngeneic mice.
    Belardelli F; Ferrantini M; Santini SM; Baccarini S; Proietti E; Colombo MP; Sprent J; Tough DF
    Cancer Res; 1998 Dec; 58(24):5795-802. PubMed ID: 9865738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells.
    Meazza R; Comes A; Orengo AM; Ferrini S; Accolla RS
    Eur J Immunol; 2003 May; 33(5):1183-92. PubMed ID: 12731043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B7-1 and interleukin 12 synergistically induce effective antitumor immunity.
    Coughlin CM; Wysocka M; Kurzawa HL; Lee WM; Trinchieri G; Eck SL
    Cancer Res; 1995 Nov; 55(21):4980-7. PubMed ID: 7585539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IFN-gamma-independent synergistic effects of IL-12 and IL-15 induce anti-tumor immune responses in syngeneic mice.
    Comes A; Di Carlo E; Musiani P; Rosso O; Meazza R; Chiodoni C; Colombo MP; Ferrini S
    Eur J Immunol; 2002 Jul; 32(7):1914-23. PubMed ID: 12115611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alloantigen-activated lymphocytes from mice bearing a spontaneous "nonimmunogenic" adenocarcinoma inhibit its growth in vivo by recruiting host immunoreactivity.
    Giovarelli M; Santoni A; Forni G
    J Immunol; 1985 Nov; 135(5):3596-603. PubMed ID: 3930610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4+ T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen.
    Kahn M; Sugawara H; McGowan P; Okuno K; Nagoya S; Hellström KE; Hellström I; Greenberg P
    J Immunol; 1991 May; 146(9):3235-41. PubMed ID: 1707934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity.
    Bannerji R; Arroyo CD; Cordon-Cardo C; Gilboa E
    J Immunol; 1994 Mar; 152(5):2324-32. PubMed ID: 7907636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nature and potential of the reactive response to mouse mammary adenocarcinoma cells engineered with interleukin-2, interleukin-4 or interferon-gamma genes.
    Musiani P; Modesti A; Brunetti M; Modica A; Vitullo P; Gulino A; Bosco MC; Colombo MP; Nanni P; Cavallo F
    Nat Immun; 1994; 13(2-3):93-101. PubMed ID: 8173240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory.
    Bosco M; Giovarelli M; Forni M; Modesti A; Scarpa S; Masuelli L; Forni G
    J Immunol; 1990 Nov; 145(9):3136-43. PubMed ID: 2212677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
    Bristol JA; Schlom J; Abrams SI
    Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.